Buy this biotech stock that can rally more than 65%, Goldman says

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Buy this biotech stock that can rally more than 65%, Goldman says

Investors should snap up Vera Therapeutics after a recent retreat, Goldman Sachs suggested. Analyst Paul Choi initiated coverage of the biotechnology stock at a buy rating. Choi’s $58 price target reflects potential for the stock to rally 66.5% from Monday’s close. Choi said positive topline results from a Vera study won’t be surprising, but should add to evidence showing the clinical differentiation of atacicept, a potential treatment for autoimmune kidney diseases. He said the firm’s model shows atacicept sales accelerating in the back half of this decade given its advantages over competitors. “Following the recent pullback, we see VERA shares at an attractive entry point given atacicept is largely de-risked with line of sight to commercialization starting next year,” Choi wrote to clients in a Monday note. Choi’s “pullback” comment refers to shares dropping more than 17% since 2025 began. However, the California-based company’s stock soared 175% in the prior year. VERA YTD mountain Vera, year to date The reasons to like Vera go beyond its shares being at an attractive entry point. Choi said the stock has a “competitive moat,” as well as a “best-in-class profile” and “substantial lead.” The analyst also said there’s “potential strategic interest” in Vera due to recent precedent transactions, as well as the potential to treat addition patients with a certain chronic kidney disease. The firm may also be able to expand its treatment focus to related diseases, he added. With his call, Choi joins the lion’s shares of analysts polled by LSEG with buy ratings on the stock.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Buy #biotech #stock #rally #Goldman

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up